# Lanreotide

> Lanreotide is a long-acting synthetic somatostatin analog approved for acromegaly and for neuroendocrine tumors, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It reduces excess growth hormone and IGF-1 secretion in acromegaly and helps control hormone-driven symptoms and, in some cases, tumor growth in functioning neuroendocrine tumors. It is formulated as a deep subcutaneous depot gel dosed roughly monthly. As a somatostatin analog, its physiologic effects extend well beyond growth hormone to other gut and pancreatic hormones.

- URL: https://www.lifeconverted.com/peptides/lanreotide
- Also known as: Somatuline
- Primary category: Other & Clinical
- Effectiveness rank: #11 in Other & Clinical
- Evidence level: Well studied
- Route: Subcutaneous (Deep subcutaneous injection, typically into the superior external quadrant of the buttock, usually administered by a healthcare provider.)
- Dose range: 60-120 mg
- Dose tiers: low 60 mg; moderate 90 mg; high 120 mg
- Half-life: Approximately 23 to 30 days for the depot formulation
- Timing: As directed by your clinician
- Cycle: Continuous monthly dosing, often long-term or indefinite depending on the condition on, Discontinued per prescriber decision off
- Storage: Refrigerate at 2-8°C, do not freeze, and protect from light; allow to reach room temperature before injection per the product label.

## Mechanism of action

Lanreotide binds somatostatin receptors, predominantly SSTR2 with some SSTR5 affinity, on pituitary somatotroph cells and neuroendocrine tissue. Receptor activation inhibits growth hormone, IGF-1, and various gastrointestinal/pancreatic hormone secretion via Gi-coupled signaling that reduces cyclic AMP.

## Reported benefits

- Normalizes GH and IGF-1 levels in acromegaly
- Controls flushing and diarrhea in carcinoid/neuroendocrine tumor syndromes
- May slow tumor growth in some gastroenteropancreatic neuroendocrine tumors
- Long-acting monthly dosing improves adherence

## Reported side effects

- Gastrointestinal upset, including diarrhea and abdominal pain
- Gallstone formation with long-term use
- Injection site nodules
- Altered glucose tolerance or hyperglycemia
- Bradycardia

## Common protocols

- Long-term GH/IGF-1 suppression in acromegaly
- Neuroendocrine tumor symptom and growth control

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer